ZIVO vs. AVIR, CMPX, CGC, ACIU, CADL, CCCC, FHTX, BNTC, URGN, and ATAI
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Atea Pharmaceuticals (AVIR), Compass Therapeutics (CMPX), Canopy Growth (CGC), AC Immune (ACIU), Candel Therapeutics (CADL), C4 Therapeutics (CCCC), Foghorn Therapeutics (FHTX), Benitec Biopharma (BNTC), UroGen Pharma (URGN), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs.
ZIVO Bioscience (NASDAQ:ZIVO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ZIVO Bioscience has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500.
ZIVO Bioscience has higher revenue and earnings than Atea Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atea Pharmaceuticals had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Atea Pharmaceuticals and 0 mentions for ZIVO Bioscience. Atea Pharmaceuticals' average media sentiment score of 1.04 beat ZIVO Bioscience's score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
ZIVO Bioscience received 81 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 60.74% of users gave ZIVO Bioscience an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote.
ZIVO Bioscience's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.
Atea Pharmaceuticals has a consensus target price of $6.88, indicating a potential upside of 104.15%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than ZIVO Bioscience.
Summary
Atea Pharmaceuticals beats ZIVO Bioscience on 10 of the 16 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ZIVO Stock Alerts